SUPPLEMENTAL TABLES

Supplemental Table 1: Classification of controlled substance stimulant dispensing by brand, product type, and short-acting (IR) or long-acting (LA/ER/SR)

|  |  |  |
| --- | --- | --- |
|  | IR Molecules | LA/ER/SR Molecules |
| Methylphenidate | Ritalin, Methylin | Ritalin SR, Metadate ER, Methylin ER, Concerta, Daytrana, Jornay PM, Metadate CD, Quillivant XR, Qullichew ER, Ritalin LA, Cotempla XR-ODT, Aptensio XR, Adhansia XR |
| Dexmethylphenidate | Focalin | Focalin XR |
| Amphetamine  | Evekeo, Evekeo ODT | Adzenys XR ODT, Adzenys ER, Dyanavel XR |
| Dextroamphetamine  |   | Dexedrine |
| Amphetamine/Dextroamphetamine | Adderall   | Adderall XR, Mydayis |
| Lisdexamfetamine |   | Vyvanse |
| Methamphetamine |   | Desoxyn |

Data Source: U.S. Food and Drug Administration

Supplemental Table 2: U.S. state- and region-specific stimulant dispensing rates per 100 persons, 2018-2019

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| State | 2018 Rate | 2019 Rate | Difference (Yearly Rates) | Region | 2018 Rate | 2019 Rate | Difference (Yearly Rates) | Rate Ratio between Regions |
| Alabama | 14.2 | 13.6 | -0.6\* | Midwest | 7.0 | 7.1 | 0.1\* | 2.6\* |
| Alaska | 2.1 | 2.2 | 0.2\* | Northeast | 5.6 | 5.8 | 0.2\* | 2.1\* |
| Arizona | 4.0 | 4.6 | 0.6\* | South | 7.7 | 7.6 | -0.1\* | 2.8\* |
| Arkansas | 10.5 | 10.1 | -0.4\* | West | 2.7 | 2.8 | 0.0\* | Referent |
| California | 1.9 | 1.8 | -0.1\* |  |  |  |  |  |
| Colorado | 4.2 | 4.3 | 0.0\* |  |  |  |  |  |
| Connecticut | 9.4 | 9.6 | 0.2\* |  |  |  |  |  |
| Delaware | 11.6 | 11.2 | -0.4\* |  |  |  |  |  |
| District of Columbia | 6.6 | 7.4 | 0.8\* |  |  |  |  |  |
| Florida | 5.3 | 4.9 | -0.4\* |  |  |  |  |  |
| Georgia | 6.3 | 6.2 | -0.1\* |  |  |  |  |  |
| Hawaii | 1.1 | 1.0 | -0.1\* |  |  |  |  |  |
| Idaho | 4.4 | 4.0 | -0.4\* |  |  |  |  |  |
| Illinois | 5.4 | 5.4 | -0.1\* |  |  |  |  |  |
| Indiana | 8.2 | 7.9 | -0.2\* |  |  |  |  |  |
| Iowa | 8.6 | 9.3 | 0.7\* |  |  |  |  |  |
| Kansas | 8.2 | 8.5 | 0.3\* |  |  |  |  |  |
| Kentucky | 6.0 | 5.9 | -0.1\* |  |  |  |  |  |
| Louisiana | 12.9 | 12.5 | -0.4\* |  |  |  |  |  |
| Maine | 10.4 | 11.4 | 1.0\* |  |  |  |  |  |
| Maryland | 8.2 | 8.6 | 0.4\* |  |  |  |  |  |
| Massachusetts | 7.5 | 8.6 | 1.1\* |  |  |  |  |  |
| Michigan | 6.8 | 7.1 | 0.3\* |  |  |  |  |  |
| Minnesota | 5.5 | 5.7 | 0.2\* |  |  |  |  |  |
| Mississippi | 9.1 | 9.1 | 0.0 |  |  |  |  |  |
| Missouri | 7.4 | 7.8 | 0.4\* |  |  |  |  |  |
| Montana | 6.5 | 7.1 | 0.6\* |  |  |  |  |  |
| Nebraska | 9.0 | 9.2 | 0.1\* |  |  |  |  |  |
| Nevada | 2.3 | 2.3 | 0.0\* |  |  |  |  |  |
| New Hampshire | 6.5 | 6.8 | 0.3\* |  |  |  |  |  |
| New Jersey | 4.6 | 4.5 | 0.0\* |  |  |  |  |  |
| New Mexico | 2.1 | 2.0 | -0.1\* |  |  |  |  |  |
| New York | 4.1 | 4.2 | 0.1\* |  |  |  |  |  |
| North Carolina | 11.1 | 11.6 | 0.5\* |  |  |  |  |  |
| North Dakota | 6.3 | 6.9 | 0.5\* |  |  |  |  |  |
| Ohio | 6.0 | 6.1 | 0.1\* |  |  |  |  |  |
| Oklahoma | 6.5 | 6.4 | -0.1\* |  |  |  |  |  |
| Oregon | 2.8 | 2.8 | 0.0\* |  |  |  |  |  |
| Pennsylvania | 5.4 | 5.4 | 0.0\* |  |  |  |  |  |
| Rhode Island | 8.2 | 9.4 | 1.3\* |  |  |  |  |  |
| South Carolina | 8.3 | 8.3 | 0.0 |  |  |  |  |  |
| South Dakota | 6.0 | 6.0 | 0.0 |  |  |  |  |  |
| Tennessee | 8.8 | 7.9 | -0.9\* |  |  |  |  |  |
| Texas | 7.0 | 6.7 | -0.2\* |  |  |  |  |  |
| Utah | 5.5 | 5.4 | -0.1\* |  |  |  |  |  |
| Vermont | 10.5 | 11.6 | 1.1\* |  |  |  |  |  |
| Virginia | 5.7 | 6.8 | 1.1\* |  |  |  |  |  |
| Washington | 3.3 | 3.4 | 0.1\* |  |  |  |  |  |
| West Virginia | 9.1 | 9.6 | 0.6\* |  |  |  |  |  |
| Wisconsin | 10.7 | 10.2 | -0.5\* |  |  |  |  |  |
| Wyoming | 4.6 | 5.4 | 0.8\* |  |  |  |  |  |

Data Source: IQVIA National Prescription Audit (NPA) New to Brand Regional

\*Significant at *P*<0.05; calculated using chi square test for statistical significance